Effects of Low-Dose Tadalafil in a Patient with Biventricular Heart Failure: A Case Report.

Abstract

Phosphodiesterase type 5 (PDE5) inhibitors such as tadalafil, can improve cardiac output by increasing left ventricular preload; however, there are concerns that this can increase the risk of heart failure due to pulmonary congestion in patients with elevated left ventricular end-diastolic pressure. We encountered a case in which low dose tadalafil improved the hemodynamics of a 66-year-old male patient with dilated cardiomyopathy (DCM) with congestion and low cardiac output due to biventricular dysfunction. The patient received a cardiac resynchronization therapy defibrillator (CRT-D) and appropriate medical therapy for heart failure. During a hemodynamic evaluation after heart failure symptoms were alleviated, we attempted to increase the dose of renin-angiotensin-aldosterone system (RAAS) inhibitors, which contribute to low cardiac output, hypotension, and worsening of renal function. However, the administration of a low dose of tadalafil for the patient's benign prostatic hyperplasia allowed for the increase in the dose of RAAS inhibitors and markedly improved his subjective symptoms and hemodynamics. Because of the biventricular dysfunction in severe cases, we often experience further promotion of low cardiac output by standard treatments such as RAAS inhibitors, in which low doses of PDE5 inhibitors may be effective in maintaining biventricular linkage. PDE5 inhibitors may be effective in patients, who are not able to increase the dose of RAAS inhibitors due to low cardiac output.

• Authors: Shoko Kono, Jinya Takahashi, Koutatsu Shimozono, Jun Kumanomido, Norikazu Inoguchi, Shoichiro Nohara, Naoki Itaya, Takaharu Nakayoshi, Yoshihiro Fukumoto
• Journal: The Tohoku journal of experimental medicine (Tohoku J Exp Med) Vol. 260 Issue 1 Pg. 87-92 (May 20 2023) ISSN: 1349-3329 [Electronic] Japan
• PMID: 36889738 (Publication Type: Case Reports, Journal Article)

Chemical References

• Tadalafil
• Phosphodiesterase 5 Inhibitors

Topics

• Male
• Humans
• Aged
• Tadalafil (therapeutic use, pharmacology)
• Phosphodiesterase 5 Inhibitors (pharmacology, therapeutic use)
• Cardiac Output, Low
• Heart Failure (complications, drug therapy)
• Hemodynamics